Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2016

Transgene Reports First Quarter 2016 Business Update

20160421 PR VEN Q1 2016 – V4 clean

Published 21 April 2016
Categorized as 2016, Press release

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition

Jean Baptiste Marchand, et al.XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016Download the poster herePoster Presentation

Published 19 April 2016
Categorized as -others, 2016, Invir.IO, Publication

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition

Jean Baptiste Marchand, et al. AACR Annual Meeting 2016, April 16-20, 2016, E.N. MorialConvention Center, New Orleans, Louisiana Download the poster here Poster Presentation

Published 19 April 2016
Categorized as -others, 2016, Publication

Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1 Monoclonal Antibody (poster)

20160419 AACR Poster PR Final

Published 19 April 2016
Categorized as 2016, Press release

Transgene Hires Two Senior Pharmaceutical Industry Executives to Join Leadership Team

20160317 Appointments PR Final

Published 17 March 2016
Categorized as 2016, Press release

Transgene Reports 2015 Financial Results and Provides Outlook for 2016 (webcast)

20160309 FY 2015 results version FINALE

Published 8 March 2016
Categorized as 2016, Press release

Transgene Announces Participation at Upcoming Investor Events

20160302 March April 2016 IR events ENG

Published 2 March 2016
Categorized as 2016, Press release

Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

20160203 PR ABL TG SYMPHONY

Published 3 February 2016
Categorized as 2016, Press release

EIB lends EUR 20m to Transgene

20160128 PR transgene BEI final version

Published 28 January 2016
Categorized as 2016, Press release

Transgene Announces Financial Calendar for 2016

20160108 financial calendar_EN ver 1

Published 8 January 2016
Categorized as 2016, Press release

Posts pagination

Newer posts Page 1 … Page 3 Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu